CorMedix Inc. (NASDAQ: CRMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
CorMedix Inc. (NASDAQ: CRMD) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance [Yahoo! Finance]
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference